Company Information

  

Address: 5 WEST FORSYTH STREET
SUITE 200 
City: JACKSONVILLE 
State: FL 
Zip Code: 32202 
Telephone: (904) 516-5436 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease. We are actively advancing our clinical programs by expanding our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart(TM) to improve the ability of the cellular immune system to recognize and destroy diseased cells. We plan to complete the pre-clinical development of our PolyStart(TM) vaccine and move it into the clinic as an integral component of a prime-boost vaccine methodology.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-1.17NAN/E
12/2017-1.16NAN/E
09/2017-1.09NAN/E
06/2017-1.04NAN/E
03/20170.16NA28.06
12/2016-0.72NAN/E
09/20161.11NA6.03
06/2016171.37NA0.04

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.07Total Liab/Total Assets0.29
Net Inc/Total Assets-2.12Total Liab/Inv Cap0.42
Net Inc/Inv Cap-3.01Total Liab/Comm Equity0.01
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/Equity0.00
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/Equity0.00
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio3.40
Inventory TurnoverNACurrent Ratio3.40
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 1.60 1.24 2.55 1.19
Operating Income -3.20 -2.68 -4.17 -2.39
Interest Exp NA NA NA NA
Pretax Income -3.20 -2.68 -3.99 -1.89
Other Income 0.00 -0.00 0.19 0.50
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -3.20 -2.68 -3.99 -1.89

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 2.80 5.13 7.61 9.96
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 2.93 5.18 7.70 10.14
Net Property, Plant & Equipment NA NA NA NA
Total Assets 2.93 5.18 7.70 10.14
Liabilities        
Accounts Payable 2.30 1.51 1.76 1.56
Debt in Current Liabilities 0.01 0.01 0.01 0.02
Total Current Liabilities 2.31 1.52 1.77 1.58
Long-Term Debt NA NA NA NA
Total Liabilities 2.31 1.52 1.77 1.58
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -160.62 -157.42 -154.74 -150.75
Treasury Stock NA NA NA NA
Total Stockholders' Equity 0.62 3.66 5.94 8.57
Total Liabilities and Stockholders' Equity 2.93 5.18 7.70 10.14

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -2.35 -2.48 -2.03 -2.01
Net Cash Provided by Investing Activities NA NA NA NA
Net Cash Provided by Financing Activities 0.02 0.00 -0.33 6.05

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-5.53--
12/20140.00-30.88--
12/20150.00-34.07--
12/20160.00-2.46-0.72
12/20170.00-10.98-1.16
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional03/31/18143382.83




Report Date : 6/18/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.